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Background—The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used in a large, multinational,
randomized, placebo-controlled trial to measure adverse effects of heart failure with preserved ejection fraction
(HF-PEF) on patients’ lives and the effects of irbesartan.
Methods and Results—Patients with symptomatic HF-PEF were randomly assigned to irbesartan (up to 300 mg daily) or
placebo. The MLHFQ was administered at baseline (n3605), month 6 (n3137), month 14 (n2904), and the end of study
(median, 56 months, n2205). Baseline MLHFQ scores of 4321 indicated that HF-PEF had a substantial adverse effects.
Estimated retest reliability was 0.80. Baseline MLHFQ scores were associated with other measures of the severity of heart
failure including symptoms, signs of congestion, cardiac structure, and time to hospitalizations or deaths attributed to heart
failure. Slight improvement in shortness of breath or fatigue was associated with significant improvement in MLHFQ scores
(5.9 and 5.0, P0.0001). Compared with placebo, further improvement in MLHFQ scores was not observed with
irbesartan after 6 months (mean adjusted difference, 0.4; 95% confidence interval, 0.8 to 1.7), 14 months (0.5; 95%
confidence interval, 0.9 to 1.8), or the end of study (2.0; 95% confidence interval, 4.1 to 0.01).
Conclusions—The MLHFQ scores are a reliable, valid, and sensitive measure of the adverse impact of HF-PEF on
patients’ lives. Irbesartan did not substantially improve MLHFQ scores during a long period of follow-up.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.
(Circ Heart Fail. 2012;5:217-225.)
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Patients with heart failure often seek medical care for reliefof symptoms, functional limitations, and psychological
distress. The MLHFQ is a measure of heart failure as
indicated by these adverse effects on patients’ lives that has
been widely used in clinical trials of heart failure with
reduced ejection (HF-REF).1–3 The effects of treatments for
HF-PEF on MLHFQ scores have not been studied as exten-
sively. The predominant cause of HF-PEF, nature of the
cardiac dysfunction, and affected population (more prevalent
among elderly women) differ from HF-REF. However,
HF-PEF and HF-REF lead to the same symptoms and
functional limitations and affect patients’ lives in similar
ways.4–6
Editorial see p 137
Clinical Perspective on p 225
The Irbesartan in Heart Failure with Preserved Systolic
Function (I-PRESERVE) trial enrolled a large number of
patients with symptomatic HF-PEF to test whether irbesartan
can reduce mortality and cardiovascular hospitalizations and
secondarily the adverse impact of HF-PEF on patients’ lives
as measured by the MLHFQ.7 A cursory report of the
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MLHFQ data indicated irbesartan did not have a significant
effect during the first 6 months of follow-up.8 When a
theoretically useful treatment for HF does not improve a
patient-reported outcome measure such as the MLHFQ, the
reliability, validity, and sensitivity of the data need to be
examined in-depth. The only other major randomized, con-
trolled trial of treating HF-PEF with an angiotensin-II recep-
tor blocker did not examine its effects on MLHFQ scores.4
Therefore, we conducted in-depth analyses of the MLHFQ
data from the I-PRESERVE Trial including longer follow-up
and assessments of the reliability, validity, and sensitivity to
change in this pivotal multinational trial.
Methods
The I-PRESERVE Trial design has been published.9 Briefly, quali-
fying patients were 60 years old with New York Heart Association
(NYHA) class II–IV symptoms and an ejection fraction 45%.
Patients who had not been hospitalized due to heart failure during the
previous 6 months were required to have NYHA class III or IV
symptoms with corroborative evidence of heart failure, or a substrate
for HF-PEF, such as ECG or echocardiographic evidence of left
ventricular hypertrophy or, if atrial fibrillation was absent, left atrial
enlargement. Treatment with an angiotensin-converting enzyme
inhibitor was permitted in up to one-third of enrolled patients who
had specific indications such as diabetes or atherosclerotic
cardiovascular disease.
Patients (n4128) were enrolled in 25 countries. The primary end
point was a composite of death from any cause or the first blindly
adjudicated hospitalization for a protocol-specified cardiovascular
cause (worsening heart failure, unstable angina, myocardial infarc-
tion, ventricular or atrial dysrhythmia, or stroke). The composite
outcome of the first hospitalization or death due to heart failure was
used to examine the predictive validity of the MLHFQ.
Investigators asked participating patients to complete the MLHFQ
at baseline, 6 and 14 months after random assignment, and the end
of study visit. Each of the 21 questions asked the patients to indicate
how much a possible effect of heart failure prevented them from
living as they wanted during the past month (30 days), using a scale
from 0 (not present or no effect), 1 (very little), 2, 3, 4, or 5 (very
much). The entire MLHFQ and its physical and emotional dimen-
sions were scored by summing responses. Patients were also asked
how much their shortness of breath and fatigue had changed since
starting study treatment using a 7-point scale of markedly, moder-
ately, or slightly improved or worsened or unchanged. Both patients
and investigators reported their global assessment of change in heart
failure using the same 7-point scale.
An echocardiography substudy that enrolled 745 subjects in sinus
rhythm to examine the effects of irbesartan on left atrial size, left
ventricular hypertrophy, and indices of diastolic function provided
several echocardiographic measures of HF-PEF that were analyzed
to help validate the MLHFQ.10
Data Analysis
First, the number of missing MLHFQ responses was examined at
each visit, and imputation was used to fill-in questionnaires with
3 missing responses. Each missing value was predicted by
regression of questions with missing responses on the best subset
of responses to other questions. Other study variables were not
used for imputation to avoid biasing estimates of their relation-
ships to MLHFQ scores. The prediction error inherent in using a
single imputed value probably would lead to underestimation of
relationships to other variables. There were no substantial differ-
ences in results when the data are analyzed without the imputed
values (complete MLHFQ only). Questionnaires with 3 missing
responses were excluded.
Distributions of patients’ responses are summarized as
meanSD. Internal consistency of the MLHFQ was assessed by
Cronbach  coefficient, a function of the mean pairwise correla-
tion between responses to all 21questions. Absent repeated
Table 1. Study MLHFQ Data
Baseline 6 Months 14 Months End of Study
Missing responses, n (%)*
0 3148 (76) 2740 (76) 2508 (86) 1912 (85)
1 (imputed) 283 (6.8) 266 (7.4) 245 (8.4) 191 (8.5)
2 (imputed) 118 (2.8) 90 (2.5) 108 (3.7) 74 (3.3)
3 (imputed) 56 (1.4) 41 (1.1) 43 (1.5) 28 (1.2)
4–20 (excluded) 45 (1.1) 36 (1.0) 29 (0.8) 35 (1.0)
Missing or blank MLHFQ form 478 (12) 468 (13) 699 (19) 1400 (39)
Deaths 0 (0) 58 (1.6) 160 (4.4) 766 (21)
Reason unknown 478 (12) 410 (11) 539 (15) 634 (18)
Distribution† of MLHFQ scores
No. of patients 3605 3137 2904 2205
Total score 42 (28–58) 32 (18–46) 30 (17–45) 30 (15–45)
Physical dimension‡ 22 (15–29) 16 (10–23) 16 (9–23) 16 (8–23)
Emotional dimension 8 (3–13) 5 (2–10) 5 (2–10) 5 (2–10)
Cronbach 
Total score 0.92 0.92 0.93 0.94
Physical dimension 0.91 0.91 0.92 0.93
Emotional dimension 0.85 0.86 0.87 0.88
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire.
*Percentage of the 4128 enrolled in the study at baseline and percentage of the number with baseline
scores (n3605) at subsequent visits.
†Median (25th to 75th percentiles).
‡See Table 2 for definition of dimensions.
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baseline administration of the MLHFQ when patients were
clinically stable, retest reliability was estimated using a path
model of the correlations between baseline, month 6, and month
14 scores to account for any changes in what is being measured
during the widely spaced measurements.11
Relationships to clinical assessments of HF-PEF including several
echocardiographic measures were examined by linear regression
analysis with robust standard errors to assess validity of the MLHFQ.
Conceptually speaking, symptoms of HF-PEF should be directly
related to MLHFQ scores. Signs and pathophysiologic measures of
HF-PEF should be indirectly related to the MLHFQ scores, depend-
ing on how strongly each relates to perceived symptoms, functional
limitations, and psychological effects of HF-PEF.
Some MLHF questions may be more or less applicable or
important, depending on the patients’ culture, lifestyle, roles, sex,
activities, and so forth. For example, working to earn a living might
be less important to elderly retired subjects. The MLHFQ scores
were related to the patients’ age, sex, and country, using multivari-
able regression analysis to adjust for any differences in assessments
of HF-PEF and comorbidity.
To examine predictive validity, baseline MLHFQ scores and
changes thereof during the first 6 months of follow-up were related
to times to subsequent hospitalizations or death attributed to heart
failure by fitting Cox regression models. The proportional hazards
assumption was tested using standardized Schoenfeld residuals. An
interaction between MLHFQ scores and follow-up time was tested and
added to model changes in the hazard ratio (HR). Cox regression models
with dummy variables representing discrete follow-up intervals, and
their interaction with MLHFQ scores were also used to estimate the
variation HRs during follow-up. All Cox models included age and sex
as covariates and were stratified by country. Clinical correlates of
MLHFQ scores and comorbidities were not included because they could
represent the same variation as MLHFQ scores.
To further evaluate construct validity and sensitivity to differences
between groups, changes in MLHFQ scores after 6 months were
compared by ANOVA of groups defined by patients’ or investiga-
tors’ ratings of changes in dyspnea, fatigue, global assessments of
heart failure, and NYHA class. Whenever the main effect of the
change categories was significant (all were P0.00001), the
MLHFQ scores in the “no change category” were compared with
other categories of change, using a Bonferroni adjustment for
multiple post hoc comparisons.
Changes in the MLHFQ scores in the groups randomly assigned
to irbesartan or placebo were compared by linear regression
analyses that included baseline MLHFQ scores, age, sex, country,
all baseline clinical assessments that were associated with
MLHFQ scores including several comorbidities (a history of
stable angina, diabetes mellitus, peripheral vascular disease,
tobacco use, ethanol abuse, chronic obstructive pulmonary dis-
ease and cancer), treatment with an angiotensin-converting en-
zyme inhibitor, and hospitalization for heart failure within 6
months before enrollment. Analyses at the end of study also
included time to discontinuation of the randomly assigned treat-
ment and use of medications typically prescribed for HF-REF.
Each follow-up visit was analyzed separately due to declining
numbers of subjects. Confidence intervals (98.3%) were adjusted
for comparing the treatment groups at 3 follow-up times
(1– 0.05/31– 0.01670.983). In addition, a longitudinal mixed
effects regression model of the individual changes in MLHFQ
scores at the 6-month, 14-month, and end-of-study (month 55 on
average) visits on time, treatment, and their interaction was used
to estimate the overall effect of irbesartan on mean MLHFQ
scores and rates of change. The intercepts (6-month change
scores) and slopes (linear rates of change between 6 months and
the end of study) were specified to be random effects with
unstructured covariance.
Stata software (version 10.1) was used for all analyses. Unless
stated otherwise, probability values and confidence intervals are
reported without adjustment for multiple comparisons.
Results
Table 1 summarizes the MLHFQ data collected at each visit.
Most respondents completed all 21 questions. Questions
about sexual activities (7.7%) and working to earn a living
(5.6%) were most frequently unanswered at baseline (and
throughout the trial). The median (25–75th percentile)
MLHFQ score at baseline was 42 (28–58). Cronbach  for
the total score was consistently 0.92. Estimated retest
reliability of the total score was 0.80 (0.80 and 0.71 for the
physical and emotional dimension scores).
Shortness of breath, fatigue, and difficulty walking or
climbing stairs had the greatest impact on these patients
with HF-PEF (Table 2). Swelling in the lower extremities
was common but had little impact. Sexual difficulties,
hospital stays, and side effects of treatments were either
not applicable during the past month (the reference period
for the questions) or had little adverse impact on the
majority of subjects.
Relationship to Clinical Assessments
Table 3 shows progressively higher (worse) MLHFQ scores
with worse NYHA class or peripheral edema. Scores were
higher when signs of circulatory congestion including pul-
monary rales, jugular venous distention, and an enlarged liver
Table 2. Baseline Distribution of MLHFQ Responses
Question About …
Response
0 (%)
Responses,*
MeanSD
1. Swelling in ankles, legs 76 1.91.5
2. Need to sit or lie down† 89 2.61.4
3. Difficulty walking, climbing stairs† 93 3.21.4
4. Difficulty with house or yard work† 88 2.81.6
5. Difficulty going places away from home† 82 2.61.7
6. Difficulty sleeping well† 77 2.11.6
7. Difficulty doing things with family or friends† 67 1.71.5
8. Difficulty working to earn a living 51 1.61.8
9. Difficulty with recreational activities 71 2.21.8
10. Difficulty with sexual activities 42 1.31.8
11. Eating less likeable foods 71 1.81.6
12. Shortness of breath† 94 3.21.4
13. Fatigue, tiredness, or low energy† 95 3.21.3
14. Hospital stay 39 1.11.6
15. Costing money for medical care 67 2.01.8
16. Treatment side effects 40 0.81.3
17. Being a burden family or friends‡ 48 1.21.5
18. Loss of self-control‡ 56 1.31.5
19. Worry‡ 81 2.21.6
20. Difficulty with concentration, memory‡ 76 2.01.6
21. Feeling depressed‡ 71 1.91.6
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire.
*Question was whether the possible effect of heart failure was present and
prevented the patient from living as they wanted during the past month ranging
from 0 (no), 1 (very little), to 5 (very much). Higher scores indicate that heart
failure with preserved ejection fraction more adversely affected patients’ lives.
†Questions included in the physical dimension.
‡Questions included in the emotional dimension.
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Table 3. Relationships Between Baseline MLHFQ Scores and Clinical Assessments
Clinical Assessment Baseline Distribution* Mean Difference† in MLFQ Score
Symptom
NYHA class
II 773 (21) Reference group
III 2730 (76) 9.3 (7.7, 11.0)¶
IV 101 (3) 25.8 (21.6, 30.0)¶
Peripheral edema
None 1658 (46) Reference group
Trace 1102 (31) 2.7 (1.1, 4.3)¶
1–2 762 (21) 7.7 (5.9, 9.4)¶
3–4 70 (2) 13.7 (9.0, 18.3)¶
Hospitalization in past 6 mo 1603 (44) 0.9 (0.4, 2.3)
Cardiovascular
Presumed etiology of heart failure
Hypertension 2349 (65) 0.8 (2.2, 0.6)
Ischemic heart disease 868 (24) 2.3 (0.7, 3.9)
Lung auscultation
Clear 2483 (69) Reference group
Wheezing only 924 (26) 4.4 (0.04, 8.8)
Basilar rales 106 (3) 5.8 (4.3, 7.4)¶
Diffuse rales 86 (2) 14.4 (10.5, 18.4)¶
Jugular venous distension 283 (8) 7.0 (4.4, 9.5)¶
Enlarged liver 701 (19) 9.1 (7.4, 10.8)¶
S3/4 gallop 297 (8) 5.3 (2.8, 7.8)¶
LV hypertrophy detected by ECG 1146 (32) 5.4 (4.0, 6.9)¶
LVEF 599 0.3/5%
60% 1780 (49) 1.1 (2.5, 0.2)
NT-proBNP, pg/mL
300 1456 (47) Reference group
301–1000 889 (29) 1.2 (3.0, 0.5)
1000 741 (24) 0.9 (1.0, 2.7)
Systolic blood pressure, mm Hg 13615 0.2 (0.5,0.02)/5 mm Hg§
Diastolic blood pressure, mm Hg 799 0.7 (0.3, 1.0)/5 mm Hg¶
Pulse pressure, mm Hg 5713 0.6 (0.9,0.4)/5 mm Hg¶
Heart rate, beats/min 7110 0.6 (0.3, 1.0)/5 beats/min¶
Left bundle-branch block 299 (8) 1.4 (1.1, 3.8)
Atrial fibrillation or flutter 598 (17) 0.5 (1.3, 2.3)
Laboratory
Serum sodium, mEq/L
135 249 (7) 1.4 (4.0, 1.3)
136–145 3209 (91) Reference group
145 82 (2) 5.4 (0.8, 9.9)§
Serum potassium, mEq/L
3.5 70 (2) 2.2 (7.1, 2.7)
3.6–5.0 3111 (88) Reference group
5.0 338 (10) 2.5 (0.2, 4.8)§
Serum albumin, g/dL
4.0 1493 (42) 0.2 (1.9, 1.5)
4.1–5.0 1000 (28) Reference group
5.0 1047 (30) 0.6 (1.2, 2.4)
Blood urea nitrogen 25 mg/dL 765 (22) 0.8 (0.9, 2.5)
(Continued)
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were present. On average, MLHFQ scores were higher in the
presence of left ventricular hypertrophy on ECG, an S3 (or
S4) gallop, an ischemic etiology, and higher heart rates.
Conversely, MLHFQ scores were lower (better) with higher
systolic and pulse pressures. The MLHFQ scores were not
related to the ejection fractions, circulating levels of natri-
uretic peptide, or measures of renal function.
From the echocardiography substudy, left atrial diameter
4.2 cm (women) or 4.6 cm (men) was positively associated
with the baseline MLHFQ scores (39%; n603; mean differ-
ence in MLHFQ score, 3.4; P0.03) as was the left ventricular
mass to end-diastolic volume ratio (n474; median, 1.8 g/mL;
25–75th percentile, 1.4–2.4; P0.03), with an estimated mean
difference in MLHFQ score of 2.5 g/mL. An E/A ratio of 0.8
(46%; n585; mean difference in MLHFQ score, 0.7; P0.66),
isovolumic relaxation time 110 ms (22%; n569; mean
difference, 2.4; P0.22), and lateral E/E ratio 15 (24%;
n446; mean difference, 3.7; P0.09) were not significantly
associated with MLHFQ scores.
Men had significantly lower adjusted MLHFQ scores
(Table 4). Average adjusted baseline MLHFQ scores in
several countries differed from the United States. Neverthe-
less, the estimated effect of irbesartan did not vary signifi-
cantly by country (interaction probability value0.82), sex
(interaction probability value0.24), or in the elderly (inter-
action probability value0.24).
Relationship to Heart Failure Morbidity
and Mortality
Of the 3605 patients who had a baseline MLHFQ score and
median follow-up of 4.3 years, 616 (17%) had an adjudicated
hospitalization or death attributed to heart failure. The inter-
action between MLHFQ scores and follow-up time was
significant (P0.0001), indicating that the hazard ratio (HR)
decreased over time from an initial value of 1.6 per 5 points
higher MLHFQ score (95% confidence interval, 1.5–1.7;
P0.0001). Estimates of HRs within sequential time inter-
vals show the downward trend from the first 6-month interval
(HR, 1.6; 95% confidence interval [CI], 1.51–1.65;
P0.0001), to the next 6-month interval (HR, 1.3; 95% CI,
1.28–1.38; P0.0001), to the second (HR, 1.2; 95% CI,
1.14–1.21; P0.0001) and third (HR, 1.05; 95% CI, 1.02–
1.08; P0.002) year of follow-up.
Changes During First 6 Months
Of the patients with a baseline MLHFQ score, 3137 (87%)
had a score at 6 months. Fifty-eight (1.6%) died before the
6-month visit, and 36 (1.0%) were missing 3 MLHFQ
Table 3. Continued
Clinical Assessment Baseline Distribution* Mean Difference† in MLFQ Score
Serum creatinine 1.5 mg/dL 219 (6) 2.5 (5.3, 0.4)
Estimated GFR, mL/min per 1.73 m2
45 331 (9) 0.6 (1.8, 3.0)
46–60 761 (22) 1.4 (0.3, 3.1)
60 2450 (69) Reference group
Hemoglobin, g/dL
12 336 (10) 1.2 (1.2, 3.6)
12–15 2379 (68) Reference group
15 785 (22) 0.7 (2.4, 1.0)
Body mass index, kg/m2 29.65.3 1.6 (1.0, 2.3)/5 kg/m2¶
Medical history‡
Stable angina 1465 (41) 3.8 (2.4, 5.2)¶
Diabetes mellitus 958 (27) 5.0 (3.4, 6.5)¶
Peripheral vascular disease 966 (27) 2.0 (0.5, 3.5)¶
Tobacco use 667 (18) 5.0 (6.8,3.3)¶
Ethanol abuse 399 (11) 8.2 (10.3,6.6)¶
COPD or adult asthma 328 (9) 2.8 (5.2,0.5)§
Cancer 200 (6) 4.0 (7.0,1.0)¶
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; LV, left
ventricular; LVEF, LV ejection fractions reported by each investigational site that used varying methods;
NT-proBNP, N-terminal pro B-type natriuretic peptide; GFR, glomerular filtration rate; and COPD, chronic
obstructive pulmonary disease.
*Summarized as n (percentage) or meanSD.
†Difference from reference group estimated as linear regression coefficients (95% confidence interval). All
other patients are the reference group for all dichotomous variables.
‡History of some conditions that could have had an effect on MLHFQ scores unrelated to heart failure with
preserved ejection fraction.
§P0.05.
P0.01.
¶P0.001.
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responses. There was a notable improvement in MLHFQ
scores in both treatment groups that persisted to the end of the
study (Table 1).
Average 6-month changes in MLHFQ scores within cate-
gories of concurrent changes in symptoms, global assess-
ments, and NYHA class are shown in Figures 1, 2, and 3.
Changes in MLHFQ scores were clearly related to patient and
investigator assessments of changes in heart failure symp-
toms. The MLHFQ scores indicated some improvement when
no change was reported in other measures. The MLHFQ
scores in the “slight symptom improvement” or 1 NYHA
class improvement categories were significantly different
(P0.001) from the respective “no change” categories as
were the slightly worse categories except the 3.3 higher mean
MLHFQ score in the slightly worse dyspnea subgroup
(n120).
Changes in MLHFQ scores during the first 6 months of
follow-up were associated with subsequent heart failure
events by Cox regression that included the baseline MLHFQ
scores. The initial HR for a 5-point increase in score was 1.2
(95% CI, 1.1–1.3; P0.0001). The interaction between the
effect of the MLHFQ score and follow-up time was also
significant (P0.0001), indicating the HR decreased during
follow-up.
Comparison of Changes in MLHFQ Scores in
Treatment Groups
As summarized in Table 5, fewer patients had MLHFQ scores at
each subsequent visit. However, the number of subjects in each
Table 4. Demographics in Relation to Baseline MLHFQ Scores
and Irbesartan Effects
Demographic
Variable
Baseline
Distribution*
Difference
in Baseline
MLHFQ Score†
Mean Effect
of Irbesartan
on Change in
MLHFQ Score
at 6 Months†
Age, y 717 0.2/5 y
65 2956 (82) 0.1 (1.5, 1.8) 0.7 (0.4, 1.9)
65 649 (18) Reference group 0.9 (3.8, 2.1)
Sex
Female 2199 (61) Reference group 1.2 (0.4, 2.8)
Male 1406 (39) 4.8 (6.1,3.4)¶ 0.05 (1.7, 1.6)
Country
United States 224 (6) Reference group 2.9 (3.7, 9.5)
Canada 71 (2) 9.4 (5.0, 13.8)¶ 1.4 (7.2, 4.5)
Mexico 150 (4) 7.1 (2.2, 12.0) 1.9 (8.2, 4.3)
Argentina 363 (10) 9.1 (5.4, 12.7)¶ 2.2 (2.0, 6.4)
Brazil 145 (4) 4.1 (0.6, 8.8) 1.6 (7.6, 4.4)
The Netherlands 213 (6) 5.8 (9.7,2.0) 1.2 (2.8, 5.3)
Germany 189 (5) 9.8 (13.6,5.9)¶ 1.0 (3.4, 5.3)
France 177 (5) 1.4 (2.9, 5.8) 2.2 (2.5, 6.8)
Spain 227 (6) 12.6 (8.2, 16.9)¶ 3.5 (0.6, 7.7)
Belgium 131 (4) 3.8 (8.6, 0.9) 0.6 (5.4, 6.6)
Poland 272 (8) 12.4 (8.3, 16.5)¶ 1.0 (2.6, 4.6)
Hungary 65 (2) 14.0 (8.2, 19.8)¶ 2.9 (10.8, 5.0)
Czechoslovakia 107 (3) 0.5 (4.5, 5.5) 2.7 (5.0, 10.3)
Russia 1017 (28) 10.3 (6.7, 14.0)¶ 0.7 (2.4, 0.9)
Other‡ 254 (7) 3.1 (6.9, 0.7) 2.2 (2.0, 6.4)
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire.
*Summarized as n (percentage) or meanSD.
†Mean difference (95% confidence interval) between groups adjusted for
significant clinical assessments and medical history listed in Table 3 and other
demographics. Tests for interaction with irbesartan effect were not significant
(elderly, P0.24; sex, P0.24; country, P0.82).
‡Other countries with 50 subjects including Australia (n38), Denmark
(n1), Greece (n19), Ireland (n9), Italy (n14), Norway (n23), Portugal
(n26), South Africa (n32), Sweden (n48), Switzerland (n1), and The
United Kingdom (n43).
§P0.05.
P0.01.
¶P0.001.
Figure 1. Mean (standard error) changes in Minnesota Living
with Heart Failure Questionnaire (MLHFQ) scores within catego-
ries of patients’ ratings of changes in dyspnea and fatigue dur-
ing the first 6 months of treatment.
Figure 2. Mean (standard error) changes in Minnesota Living
with Heart Failure Questionnaire (MLHFQ) scores within catego-
ries of patients’ and investigators’ global ratings of changes in
heart failure during first 6 months of treatment.
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treatment group, distributions of baseline MLHFQ scores, per-
centages that discontinued the assigned treatment including
interim mortality, and percentages treated with other medica-
tions that could affect MLHFQ scores were similar. The mean
adjusted differences between treatment groups in the total
MLHFQ score were not significant at any visit.
The longitudinal regression analysis found a very small
annual rate of reduction of 0.4/y (95% CI, 0.1–0.6/y,
P0.01) in the initial 6-month improvement in MLHFQ
scores in the placebo group. Compared with the placebo
group, irbesartan prevented this slow worsening of MLHFQ
scores (difference 0.6/y; 95% CI, 1.0 to 0.2; P0.003).
Averaging over all 3 visits, the difference in changes in
MLHFQ scores between the irbesartan and placebo groups
was not significant (0.8; 95% CI, 0.4 to 2.0; P0.20).
Separate analyses of the physical and emotional dimension
scores found very similar results that are not reported.
Discussion
The median MLHF scores of 42 (quartiles 28–58) at baseline
indicate HF-PEF adversely affected the lives of the majority
of patients enrolled in the I-PRESERVE Trial, of whom 75%
had NYHA class III symptoms at baseline. All 21 questions
were pertinent to substantial proportions of these symptom-
atic patients and their responses were highly internally
consistent, suggesting that all responses were related to the
same phenomenon, presumably HF-PEF. In the Candesartan
in Heart Failure Assessment of Reduction in Mortality and
Morbidity (CHARM) study of HF-PEF, the distribution of
scores among NYHA class III patients was 48 (32–67) and
Figure 3. Mean (standard error) changes in Minnesota Living
with Heart Failure Questionnaire (MLHFQ) scores within catego-
ries of changes in New York Heart Association (NYHA) class.
Table 5. Changes in MLHFQ Scores Within Treatment Groups
6 Months 14 Months End of Study*
Irbesartan Placebo Irbesartan Placebo Irbesartan Placebo
Subjects, n (%)† 1567 (87) 1570 (87) 1446 (81) 1458 (81) 1102 (61) 1103 (61)
Discontinued study treatment, % 6.7 7.0 13 11 40 40
Adverse event 2.9 2.8 5.7 4.3 15 13
Mortality 1.6 1.6 4.5 4.4 21 20
Concurrent meds, %
ACE inhibitor 22 25 26 23 30 27
-blocker 60 61 61 60 65 64
Diuretic 82 87 87 84 86 81
Loop diuretic 62 60 60 61 61 61
Spiranolactone 18 19 19 18 21 16
CaCB 34 39 40 36 40 36
Baseline score 4321 4321 4321 4320 4321 4220
Changes in score 9.718 9.717 12.019 12.218 11.923 9.623
Unadjusted mean difference (98.3% CI)
Total score 0.0 (1.5, 1.5) 0.2 (1.4, 1.9) 2.3 (4.6, 0.01)
Physical dimension 0.0 (0.7, 0.7) 0.4 (0.4, 1.2) 0.8 (1.9, 0.3)
Emotional dimension 0.1 (0.6, 0.3) 0.1 (0.6, 0.4) 0.6 (1.3, 0.02)
Adjusted‡ mean difference (98.3% CI)
Total score 0.4 (0.8, 1.7) 0.5 (0.9, 1.8) 2.0 (4.1, 0.01)
Physical dimension 0.2 (0.5, 0.8) 0.5 (0.2, 1.2) 0.7 (1.6, 0.3)
Emotional dimension 0.0 (0.4, 0.4) 0.1 (0.5, 0.4) 0.6 (1.2,0.01)
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire; ACE, angiotensin-converting enzyme inhibitor; CaCB, calcium channel blocker; CI, confidence
interval.
*Median, 56; interquartile range, 50–62 months after baseline visit.
†Baseline MLHFQ score included 1795 patients in the irbesartan group and 1810 in the placebo group.
‡Baseline MLHFQ score, age, sex, country, all significant baseline clinical assessments, and comorbidities (in Table 3) and whether the subject was treated with
an angiotensin-converting enzyme inhibitor or hospitalized for heart failure within 6 months before enrollment are included as covariates in the regression model.
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27 (15–48) for class II patients.4. The distributions of
MLHFQ scores in the CHARM study of patients with
HF-REF and NYHA class II (26, 13–47) or III (44, 25–62)
heart failure were very similar. The distribution of MLHFQ
scores in I-PRESERVE is also similar to other studies of
HF-REF 12–14 Thus, depending on the patients’ symptoms and
functional limitations, heart failure has similar adverse effects
on patients’ lives regardless of their ejection fraction.
In-depth analysis of MLHFQ data collected by the
I-PRESERVE investigators did not reveal clinically signifi-
cant effects of irbesartan after 6, 14, or a median of 56 months
of follow-up. This result is consistent with a much smaller
open-label study of patients with HF-PEF given lower doses
of irbesartan (75 mg, n56) that did not see more improve-
ment in MLHFQ scores after 12, 24, or 52 weeks than seen
with diuretic therapy (n50).15 These are the only 2 studies
we know that used the MLHFQ to evaluate an angiotensin
receptor antagonist for HF-PEF.
The lack of an irbesartan effect could not be attributed to
the measurement performance of the MLHFQ in this multi-
national study. The estimated retest reliability coefficient of
0.80 was sufficient for comparing treatment groups. Changes
in MLHFQ scores in subgroups that had only slightly better
or worse symptoms of heart failure or a change in one NYHA
class were significantly different from those that did not
change. The baseline MLHFQ scores were related to left
atrial enlargement and left ventricular mass–to–volume ratio
that were also independently associated with other study end
points.10 Baseline and changes in MLHFQ scores over 6
months were also associated with the end point of hospital-
izations or deaths attributed to heart failure. Therefore, the
reliability, validity, and sensitivity of the MLHFQ in this
study of HF-PEF were sufficient to detect a treatment effect
and similar to what has been reported in studies of patients
with HF-REF.2,12,16–18
A substantial improvement in the MLHFQ scores occurred
in both treatment groups during the first 6 months of
follow-up and persisted in those followed to the end of the
study. Similar improvements have been seen in some but not
all studies of medications and disease management programs
for patients with HF-REF.19–24 Further unreported analysis of
the MLHFQ scores in the placebo group indicated that the
changes in the first 6 months were related to baseline scores
(perhaps regression to the mean), country, sex, and age.
Adjustments were made for all of these factors when estimat-
ing the effect of irbesartan. The 6-month estimates of the
irbesartan effect did not vary significantly across countries,
age groups, or sex. Thus, we do not believe the changes in
MLHFQ scores seen in the placebo group during the first 6
months masked an irbesartan effect.
Although the number in each treatment group that died or
were lost to follow-up were similar at each visit as were the
baseline MLHFQ scores of the remaining subjects, unrecog-
nized differences between the subjects remaining in each group
and the reasons for the nonrandom losses during follow-up could
have biased the long-term comparisons. Unreported compari-
sons of subjects that provided MLHFQ data at all follow-up
visits showed essentially the same group trends and differences
as did the longitudinal regression analyses.
The observed differences between countries in adjusted
MLHFQ scores may be related to differences in language,
culture, translation, and perhaps medical care for HF-PEF.
Why women reported their lives were more adversely af-
fected by HF-PEF is not known. The difference was not due
to any particular questions. As much as possible, adjustments
were made for any differences between sexes in the severity
of symptoms and clinical assessments of HF-PEF, comorbidi-
ties, age, and country. The observed sex difference is consis-
tent with other studies of patients with HF-PEF and HF-
REF.4,12,13 More to the point, the significant unexplained
variation in MLHFQ scores between country and sex did not
explain the lack of benefit from irbesartan.
In summary, irbesartan did not reduce the substantial
adverse impact of symptomatic HF-PEF on patients’ lives in
the I-PRESERVE Trial. In-depth analyses indicate the lack of
benefit was not due to lack of reliability, validity, or sensi-
tivity of the MLHFQ in this large, multinational clinical trial.
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CLINICAL PERSPECTIVE
Patients with heart failure often seek medical care for relief of symptoms, functional limitations, and psychological distress
that adversely affect their quality of life. The multinational Irbesartan in Heart Failure with Preserved Systolic Function
(I-PRESERVE) trial enrolled a large number of patients with symptomatic heart failure with preserved ejection fraction
(HF-PEF) to test whether irbesartan can reduce mortality and cardiovascular hospitalizations and secondarily the adverse
impact of heart failure on quality of life as measured by the Minnesota Living with Heart Failure Questionnaire. In-depth
analyses indicated that the Minnesota Living with Heart Failure Questionnaire scores provided a reliable, valid, and
sensitive measure of the adverse effects of heart failure with preserved ejection fraction on patients’ lives. Although the
quality of subjects’ lives was adversely affected at baseline, there was no indication that irbesartan reduced the adverse
effects during more than 4 years of follow-up.
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